


Healthcare News Roundup: Biopharmaceutical
HSMN NewsFeed - 7 Aug 2018
Infinity Pharmaceuticals Appoints Samuel Agresta, M.D., M.P.H. as Chief Medical Officer
Infinity Pharmaceuticals Appoints Samuel Agresta, M.D., M.P.H. as Chief Medical Officer
HSMN NewsFeed - 6 Aug 2018
US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA(TM) (lofexidine) 0.18 Mg Tablets
US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA(TM) (lofexidine) 0.18 Mg Tablets
HSMN NewsFeed - 1 Aug 2018
Oncorus(R), Inc., Names Industry Veteran Ted Ashburn as new President and CEO
Oncorus(R), Inc., Names Industry Veteran Ted Ashburn as new President and CEO
HSMN NewsFeed - 30 Jul 2018
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
HSMN NewsFeed - 30 Jul 2018
Enzyvant Expands Leadership Team with Appointments of Andrew Dawson and Alex Tracy
Enzyvant Expands Leadership Team with Appointments of Andrew Dawson and Alex Tracy
HSMN NewsFeed - 27 Jul 2018
Accord Healthcare’s (Intas) Pelgraz(R) (pegfilgrastim) Given Green Light by CHMP
Accord Healthcare’s (Intas) Pelgraz(R) (pegfilgrastim) Given Green Light by CHMP
HSMN NewsFeed - 26 Jul 2018
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE(R) Technology
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE(R) Technology
HSMN NewsFeed - 24 Jul 2018
Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders
Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders
HSMN NewsFeed - 24 Jul 2018
Soligenix Announces Appointment of Mark Pearson to its Board of Directors
Soligenix Announces Appointment of Mark Pearson to its Board of Directors
HSMN NewsFeed - 23 Jul 2018
Amneal Announces FDA Approval and Launch of Generic Potassium Chloride Oral Solution
Amneal Announces FDA Approval and Launch of Generic Potassium Chloride Oral Solution
HSMN NewsFeed - 19 Jul 2018
BioPharmX Announces FDA Grant of CARC Waiver and Post-Hoc Analysis for BPX-01
BioPharmX Announces FDA Grant of CARC Waiver and Post-Hoc Analysis for BPX-01
HSMN NewsFeed - 19 Jul 2018
Genesis Drug Discovery & Development Appoints Olesia Buiakova, M.D., Ph.D., as Chief Scientific Officer
Genesis Drug Discovery & Development Appoints Olesia Buiakova, M.D., Ph.D., as Chief Scientific Officer
HSMN NewsFeed - 18 Jul 2018
PainReform Gets FDA Approval for Phase III Post-Operative Pain Relief Study
PainReform Gets FDA Approval for Phase III Post-Operative Pain Relief Study
HSMN NewsFeed - 17 Jul 2018
Spruce Biosciences Appoints David Moriarty, Ph.D., as Vice President of Development Operations
Spruce Biosciences Appoints David Moriarty, Ph.D., as Vice President of Development Operations
HSMN NewsFeed - 16 Jul 2018
Pliant Therapeutics Raises $62 Million in Series B Financing to Advance Therapies for Fibrotic Diseases
Pliant Therapeutics Raises $62 Million in Series B Financing to Advance Therapies for Fibrotic Diseases
HSMN NewsFeed - 16 Jul 2018
enGene Appoints Veteran Life Sciences Executive Jason D. Hanson as Chief Executive Officer and President
enGene Appoints Veteran Life Sciences Executive Jason D. Hanson as Chief Executive Officer and President
HSMN NewsFeed - 13 Jul 2018
Modus Therapeutics Completes a SEK 140 Million Financing led by HealthCap
Modus Therapeutics Completes a SEK 140 Million Financing led by HealthCap
HSMN NewsFeed - 13 Jul 2018
Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY(TM) (romosozumab) To The US FDA
Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY(TM) (romosozumab) To The US FDA
HSMN NewsFeed - 11 Jul 2018
FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
HSMN NewsFeed - 9 Jul 2018
Mylan Adds to Central Nervous System Portfolio With Launch of Generic Exelon(R) Patch
Mylan Adds to Central Nervous System Portfolio With Launch of Generic Exelon(R) Patch
HSMN NewsFeed - 9 Jul 2018
Polaris Announces Drs. James Allison and Padmanee Sharma Joining its Scientific Advisory Board
Polaris Announces Drs. James Allison and Padmanee Sharma Joining its Scientific Advisory Board
HSMN NewsFeed - 29 Jun 2018
Amneal Announces Favorable Ruling Regarding Patent Validity for Zomig(R) (zolmitriptan) Nasal Spray
Amneal Announces Favorable Ruling Regarding Patent Validity for Zomig(R) (zolmitriptan) Nasal Spray
HSMN NewsFeed - 28 Jun 2018
Corporate Biotech Executive Mark Germain Joins BiondVax's Board of Directors
Corporate Biotech Executive Mark Germain Joins BiondVax's Board of Directors
HSMN NewsFeed - 28 Jun 2018
Lupin and Mylan Partner to Commercialize Enbrel(R) (Etanercept) Biosimilar
Lupin and Mylan Partner to Commercialize Enbrel(R) (Etanercept) Biosimilar
HSMN NewsFeed - 27 Jun 2018
ANI Pharmaceuticals Announces Launch of Cholestyramine for Oral Suspension USP
ANI Pharmaceuticals Announces Launch of Cholestyramine for Oral Suspension USP
HSMN NewsFeed - 25 Jun 2018
Cronos Group Inc. Announces Exclusive Distribution Agreement with Delfarma in Poland
Cronos Group Inc. Announces Exclusive Distribution Agreement with Delfarma in Poland
HSMN NewsFeed - 21 Jun 2018
AdoRx Therapeutics Announces Initial Funding of $10 Million for the Discovery of New Cancer Therapeutics
AdoRx Therapeutics Announces Initial Funding of $10 Million for the Discovery of New Cancer Therapeutics
HSMN NewsFeed - 20 Jun 2018
Amneal Announces Patent Litigation Settlement Agreement with Actavis Concerning Rytary(R)
Amneal Announces Patent Litigation Settlement Agreement with Actavis Concerning Rytary(R)
HSMN NewsFeed - 18 Jun 2018
Mallinckrodt Reports Interim Findings Of H.P. Acthar(R) Gel (Repository Corticotropin Injection) Studies
Mallinckrodt Reports Interim Findings Of H.P. Acthar(R) Gel (Repository Corticotropin Injection) Studies
HSMN NewsFeed - 18 Jun 2018
Proposed Remetinostat Phase III Design Results in Delay in Planned Start of Study
Proposed Remetinostat Phase III Design Results in Delay in Planned Start of Study
HSMN NewsFeed - 15 Jun 2018
MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress
MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress
HSMN NewsFeed - 13 Jun 2018
BridgeBio Pharma Launches CoA Therapeutics to Target Coenzyme-A for Rare Genetic Disorders
BridgeBio Pharma Launches CoA Therapeutics to Target Coenzyme-A for Rare Genetic Disorders
HSMN NewsFeed - 13 Jun 2018
StrideBio Closes $15.7 Million Series A Financing to Advance Transformational AAV Platform
StrideBio Closes $15.7 Million Series A Financing to Advance Transformational AAV Platform
